Reduced ultraviolet-induced carcinogenesis in mice with a functional disruption in B7-mediated costimulation

Journal of Immunology

Volumn 163, Issue 12, 1999, Pages 6725-6731

  Beissert, Stefan ^a   Bluestone, Jeffrey A ^b   Mindt, Iris ^a   Voskort, Maik ^a   Metze, Dieter ^a   Mehling, Annette ^a   Luger, Thomas A ^a   Schwarz, Thomas ^a   Grabbe, Stephan ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; B7 ANTIGEN; CD86 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 4; MITOGENIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HELPER CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CANCER; T LYMPHOCYTE ACTIVATION; TRANSGENE; ULTRAVIOLET IRRADIATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; CELLS, CULTURED; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, RADIATION-INDUCED; SKIN NEOPLASMS; TH2 CELLS; ULTRAVIOLET RAYS;

EID: 0032715357     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Urbach, F. 1997. Ultraviolet radiation and skin cancer of humans. J. Photochem. Photobiol. B 40:3.
2. Kricker, A., B. K. Armstrong, and D. M. Parkin. 1993. Measurement of skin cancer incidence. Health Rep. 5:63.
3. Kelfkens, G., F. R. deGruijl, and J. C. van der Leun. 1990. Ozone depletion and increase in annual carcinogenic ultraviolet dose. Photochem. Photobiol. 52:819.
4. Boyle, J., J. D. Briggs, R. M. MacKie, B. J. R. Junor, and T. C. Artchison. 1984. Cancer, warts and sunshine in renal transplant patients. Lancet 1:702.
5. Marshall, V. 1974. Premalignant and malignant skin tumours in immunosuppression patients. Transplantation 17:272.
6. Kripke, M. L. 1974. Antigenicity of murine skin tumors induced by ultraviolet light. J. Natl. Cancer Inst. 53:1333.
7. Kripke, M. L. 1977. Latency, histology, and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains. Cancer Res. 37:1395.
8. Fischer, M. S., and M. L. Kripke. 1982. Suppressor T lymphocytes control the development of primary skin cancer in ultraviolet-irradiated mice. Science 216: 1133.
9. Grabbe, S., S. Bruvers, R. L. Gallo, T. L. Knisely, R. Nazareno, and R. D. Granstein. 1991. Tumor antigen presentation by murine epidermal cells. J. Immunol. 146:3656.
10. Grabbe, S., S. Bruvers, A. M. Lindgren, J. Hosoi, K. C. Tan, and R. D. Granstein. 1992. Tumor antigen presentation by epidermal Ag-presenting cells in the mouse: modulation by granulocyte-macrophage colony-stimulating factor, tumor necrosis factor α, and ultraviolet radiation. J. Leukocyte Biol. 52:202.
11. Beissert, S., and R. D. Granstein. 1996. UV-induced cutaneous photobiology. Crit. Rev. Biochem. Mol. Biol. 31:381.
12. Ullrich, S. E. 1995. Modulation of immunity by ultraviolet radiation: key effects on antigen presentation. J. Invent. Dermatol. 105:30S-36S.
13. Lenschow, D. J., Y. Zeng, J. R. Thistlethwaite, A. Montag, W. Brady, M. G. Gibson, P. S. Linsley, and J. A. Bluestone. 1992. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 257:789.
14. Thompson, C. B. 1995. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 81:979.
15. Boussiotis, V. A., J. G. Gribben, G. J. Freeman, and L. M. Nadler. 1994. Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. Curr. Opin. Immunol. 6:797.
16. Tang, A., T. A. Judge, B. J. Nickoloff, and L. A. Turka. 1996. Suppression of murine allergic contact dermatitis by CTLA4Ig: tolerance induction of Th2 responses requires additional blockade of CD40-ligand. J. Immunol. 157:117.
17. Hodge, J. W., S. Abrams, J. Schlom, and J. A. Kantor. 1994. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 co-stimulatory molecules. Cancer Res. 54:5552.
18. Geldhof, A. B., G. Raes, M. Bakkus, S. Devos, K. Thielemans, and P. De Baetselier. 1995. Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res. 55:2730.
19. Yang, G., K. E. Hellstrom, I. Hellstrom, and L. Chen. 1995. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154:2794.
20. Krummel, M. F., and J. P. Allison. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182:459.
21. Rulifson, I. C., A. I. Sperling, P. E. Fields, F. W Fitch, and J. A. Bluestone. 1997. CD28 co-stimulation promotes the production of Th2 cytokines. J. Immunol. 158:658.
22. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405.
23. Leach, D. R., M. F. Krummel, and J. P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734.
24. Lenschow, D. J., K. C. Herold, L. Rhee, B. Patel, A. Koons, H. Y. Qin, E. Fuchs, B. Singh, C. B. Thompson, and J. A. Bluestone. 1996. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 5:285.
25. Urban, J. L., R. C. Burton, J. M. Holland, M. L. Kripke, and H. Schreiber. 1982. Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J. Exp. Med. 155:557.
26. Urban, J. L., M. L. Kripke, and H. Schreiber. 1986. Stepwise immunologic selection of antigenic variants during tumor growth. J. Immunol. 137:3036.
27. Beissert, S., J. Hosoi, R. Kühn, K. Rajewsky, W. Müller, and R. D. Granstein. 1996. Impaired immunosuppressive response to ultraviolet radiation in interleukin-10-deficient mice. J. Invest. Dermatol. 107:553.
28. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Maramatsu, and R. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony stimulating factor. J. Exp. Med. 176:1693.
29. Röcken, M., J. Urban, and E. M. Shevach. 1994. Antigen-specific activation, tolerization, and reactivation of the interleukin 4 pathway in vivo. J. Exp. Med. 179:1885.
30. Peto, R., M. C. Pike, P. Armitage, N. E. Breslow, D. R. Cox, S. V. Howard, N. Mantel, K. McPherson, J. Peto, and P. G. Smith. 1977. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer 35:1.
31. Khar, A., S. Kausalaya, and M. A. Kamal. 1996. AK-5 tumor-induced modulation of host immune function: up-regulation of Th1-type cytokine response mediates early tumor regression. Cytokines Mol. Ther. 2:39.
32. Aruga, A., E. Aruga and A. E. Chang. 1997. Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant. Cancer Res. 57:3230.
33. Vile, R. G., S. Castleden, J. Marshall, R. Camplejohn, C. Upton, and H. Chong. 1997. Generation of an antitumor immune response in a nonimmunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int. J. Cancer 71:267.
34. Shreedhar, V., T. Giese, V. W. Sung, and S. E. Ullrich. 1998. A cytokine cascade including prostaglandin E2, IL-4, and IL-10 is responsible for UV-induced systemic immune suppression. J. Immunol. 160:3783.
35. Ward, P. L., H. Koeppen, T. Hurteau, and H. Schreiber. 1989. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J. Exp. Med. 170:217.
36. Green, J. M., P. J. Noel, T. L. Walunas, G. S. Gray, J. A. Bluestone, and C. B. Thompson. 1994. Absence of B7-dependent responses in CD28-deficient mice. Immunity 1:501.
37. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707.
38. King, C. L., J. Xianli, C. H. June, R. Abe, and K. P. Lee. 1996. CD28-deficient mice generate an impaired Th2 response to Schistosoma mansoni infection. Eur. J. Immunol. 26:2448.
39. Corry, D. B., S. L. Reiner, P. S. Linsley, and R. M. Locksley. 1994. Differential effects of blockade of CD28 -B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. J. Immunol. 153:4142.
40. Lu, P., X. D. Zhou, S.-J. Chen, M. Moorman, A Schoneveld, S. Morris, F. D. Finkelman, P. Linsley, E. Claassen, and W. C. Gause. 1995. Requirement of CTLA-4 counter receptors for IL-4 but not IL-10 elevations during primary systemic immune response. J. Immunol. 154:1078.